MET and neoplasm: Mechanistically, when c-MET is amplified or overexpressed, it can bypass EGFR pathway inhibition through the ERBB3 receptor-mediated PI3K/AKT and Grb2/MAPK pathways, thereby maintaining tumor cell growth and survival [85].